UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Clinical kidney journal, 2018-12, Vol.11 (6), p.749-761

2018

Volltextzugriff (PDF)

BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes

Expert opinion on pharmacotherapy, 2024-01, Vol.25 (2), p.127-130

2024

Volltextzugriff (PDF)

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Cardiovascular diabetology, 2018-01, Vol.17 (1), p.5-8, Article 5

2018

Volltextzugriff (PDF)

Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial

Diabetes, obesity & metabolism, 2022-05, Vol.24 (5), p.816-826

2022

Volltextzugriff (PDF)

Molecular regulation of the renin–angiotensin system by sodium–glucose cotransporter 2 inhibition in type 1 diabetes mellitus

Diabetologia, 2019-06, Vol.62 (6), p.1090-1093

2019

Volltextzugriff (PDF)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

British journal of clinical pharmacology, 2020-11, Vol.86 (11), p.2192-2203

2020

Volltextzugriff (PDF)

Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet

Biomedicine & pharmacotherapy, 2024-05, Vol.174, p.116520-116520, Article 116520

2024

Volltextzugriff (PDF)

Canagliflozin in der Monotherapie: Klinische Studiendaten bei Diabetes mellitus Typ 2

Deutsche medizinische Wochenschrift, 2014-02, Vol.139 (S 02), p.S59-S64

Matthaei, S.

2014

Volltextzugriff (PDF)

Orale Add-on-Therapie zu Metformin bei Typ-2-Diabetes mellitus: Canagliflozin und Glimepirid im direkten Vergleich

Deutsche medizinische Wochenschrift, 2014-02, Vol.139 (S 02), p.S65-S69

Seufert, J.

2014

Volltextzugriff (PDF)

Orale Add-on-Therapie zu Metformin bei Typ-2-Diabetes mellitus: Canagliflozin und Sitagliptin im direkten Vergleich

Deutsche medizinische Wochenschrift, 2014-02, Vol.139 (S 02), p.S70-S74

Schnell, O.

2014

Volltextzugriff (PDF)

Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?

Diabetes, obesity & metabolism, 2019-04, Vol.21 (S2), p.24-33

2019

Volltextzugriff (PDF)

Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study

Hormone and metabolic research, 2018-05, Vol.50 (5), p.403-407

2018

Volltextzugriff (PDF)

Different glucagon effects during DPP‐4 inhibition versus SGLT‐2 inhibition in metformin‐treated type 2 diabetes patients

Diabetes, obesity & metabolism, 2018-07, Vol.20 (7), p.1652-1658

2018

Volltextzugriff (PDF)

Effects on α‐ and β‐cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study

Diabetes, obesity & metabolism, 2017-04, Vol.19 (4), p.489-495

2017

Volltextzugriff (PDF)

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes

Endocrinology, diabetes & metabolism, 2020-07, Vol.3 (3), p.e00129-n/a

2020

Volltextzugriff (PDF)

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease

Biomedicines, 2022-10, Vol.10 (10), p.2509

2022

Volltextzugriff (PDF)

Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?

Diabetologia, 2015-08, Vol.58 (8), p.1740-1744

Ahrén, Bo

2015

Volltextzugriff (PDF)

Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions

Cardiovascular & hematological disorders drug targets, 2018, Vol.18 (2), p.86-93

2018

Volltextzugriff (PDF)

Inhibition der Glukosereabsorption im proximalen Tubulus – Neues Therapieprinzip bei Typ-2-Diabetes

Diabetes aktuell, 2010-05, Vol.8 (3), p.131-135

2010

Volltextzugriff (PDF)

New Antidiabetic Agents for the Treatment of Heart Failure in Hypertensive Patients

Hypertension and Heart Failure : Epidemiology, Mechanisms and Treatment - Epidemiology, Mechanisms and Treatment, 2024, p.79

2024

Volltextzugriff (PDF)

Future and Novel Compounds in the Treatment of Diabetic Nephropathy

Diabetic Nephropathy, p.515-539

Volltextzugriff (PDF)

Weight loss associated with sodium‐glucose cotransporter‐2 inhibition: a review of evidence and underlying mechanisms

Obesity reviews, 2018-12, Vol.19 (12), p.1630-1641

2018

Volltextzugriff (PDF)

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes

Diabetes research and clinical practice, 2020-12, Vol.170, p.108462, Article 108462

2020

Volltextzugriff (PDF)

Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs

Cardiovascular & hematological disorders drug targets, 2018, Vol.18 (2), p.104-113

2018

Volltextzugriff (PDF)

Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits

Cardiovascular & hematological disorders drug targets, 2018, Vol.18 (2), p.114-119

2018

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(23)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Sglt-2 Inhibition
(20)
Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Diabetes
(11)
Endocrinology & Metabolism
(11)
Humans
(11)
Diabetes Mellitus
(10)
Diabetes Mellitus, Type 2 - Drug Therapy
(10)
Glucose
(9)
Sodium
(9)
Blood Pressure
(8)
Male
(8)
Type 2 Diabetes
(8)
Female
(7)
Hyperglycemia
(6)
Aged
(5)
Body Weight
(5)
Diabetes Mellitus, Type 2 - Blood
(5)
Middle Aged
(5)
Sglt‐2 Inhibition
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes

SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial

Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial

Molecular regulation of the renin–angiotensin system by sodium–glucose cotransporter 2 inhibition in type 1 diabetes mellitus

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials

Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet

Canagliflozin in der Monotherapie: Klinische Studiendaten bei Diabetes mellitus Typ 2

Orale Add-on-Therapie zu Metformin bei Typ-2-Diabetes mellitus: Canagliflozin und Glimepirid im direkten Vergleich

Orale Add-on-Therapie zu Metformin bei Typ-2-Diabetes mellitus: Canagliflozin und Sitagliptin im direkten Vergleich

Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?

Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study

Different glucagon effects during DPP‐4 inhibition versus SGLT‐2 inhibition in metformin‐treated type 2 diabetes patients

Effects on α‐ and β‐cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease

Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?

Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions

Inhibition der Glukosereabsorption im proximalen Tubulus – Neues Therapieprinzip bei Typ-2-Diabetes

New Antidiabetic Agents for the Treatment of Heart Failure in Hypertensive Patients

Future and Novel Compounds in the Treatment of Diabetic Nephropathy

Weight loss associated with sodium‐glucose cotransporter‐2 inhibition: a review of evidence and underlying mechanisms

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes

Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs

Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits

Suchergebnisse filtern